Literature DB >> 27472820

Standardised surveillance of Clostridium difficile infection in European acute care hospitals: a pilot study, 2013.

Sofie M van Dorp1, Pete Kinross, Petra Gastmeier, Michael Behnke, Axel Kola, Michel Delmée, Anastasia Pavelkovich, Silja Mentula, Frédéric Barbut, Agnes Hajdu, André Ingebretsen, Hanna Pituch, Ioana S Macovei, Milica Jovanović, Camilla Wiuff, Daniela Schmid, Katharina Ep Olsen, Mark H Wilcox, Carl Suetens, Ed J Kuijper.   

Abstract

Clostridium difficile infection (CDI) remains poorly controlled in many European countries, of which several have not yet implemented national CDI surveillance. In 2013, experts from the European CDI Surveillance Network project and from the European Centre for Disease Prevention and Control developed a protocol with three options of CDI surveillance for acute care hospitals: a 'minimal' option (aggregated hospital data), a 'light' option (including patient data for CDI cases) and an 'enhanced' option (including microbiological data on the first 10 CDI episodes per hospital). A total of 37 hospitals in 14 European countries tested these options for a three-month period (between 13 May and 1 November 2013). All 37 hospitals successfully completed the minimal surveillance option (for 1,152 patients). Clinical data were submitted for 94% (1,078/1,152) of the patients in the light option; information on CDI origin and outcome was complete for 94% (1,016/1,078) and 98% (294/300) of the patients in the light and enhanced options, respectively. The workload of the options was 1.1, 2.0 and 3.0 person-days per 10,000 hospital discharges, respectively. Enhanced surveillance was tested and was successful in 32 of the hospitals, showing that C. difficile PCR ribotype 027 was predominant (30% (79/267)). This study showed that standardised multicountry surveillance, with the option of integrating clinical and molecular data, is a feasible strategy for monitoring CDI in Europe. This article is copyright of The Authors, 2016.

Entities:  

Keywords:  Clostridium difficile; Clostridium infections in humans; Europe; Typing; epidemiology; surveillance

Mesh:

Year:  2016        PMID: 27472820     DOI: 10.2807/1560-7917.ES.2016.21.29.30293

Source DB:  PubMed          Journal:  Euro Surveill        ISSN: 1025-496X


  14 in total

1.  Increasing incidence of Clostridium difficile ribotype 001 associated with severe course of the infection and previous fluoroquinolone use in the Czech Republic, 2015.

Authors:  M Krutova; J Matejkova; P Drevinek; E J Kuijper; O Nyc
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-07-05       Impact factor: 3.267

2.  Influence of Binary Toxin Gene Detection and Decreased Susceptibility to Antibiotics among Clostridioides difficile Strains on Disease Severity: a Single-Center Study.

Authors:  Deiziane V S Costa; Natalie V S Pham; Rachel A Hays; David T Bolick; Sophia M Goldbeck; Melinda D Poulter; Sook C Hoang; Jae H Shin; Martin Wu; Cirle A Warren
Journal:  Antimicrob Agents Chemother       Date:  2022-07-21       Impact factor: 5.938

3.  Epidemiology and outcome of Clostridium difficile infections in patients hospitalized in Internal Medicine: findings from the nationwide FADOI-PRACTICE study.

Authors:  Giorgio Cioni; Pierluigi Viale; Stefania Frasson; Francesco Cipollini; Francesco Menichetti; Nicola Petrosillo; Sergio Brunati; Patrizia Spigaglia; Chiara Vismara; Alessandra Bielli; Fabrizio Barbanti; Giancarlo Landini; Grazia Panigada; Gualberto Gussoni; Erminio Bonizzoni; Giovanni Pietro Gesu
Journal:  BMC Infect Dis       Date:  2016-11-08       Impact factor: 3.090

Review 4.  Risk factors for Clostridium difficile infections - an overview of the evidence base and challenges in data synthesis.

Authors:  Paul Eze; Evelyn Balsells; Moe H Kyaw; Harish Nair
Journal:  J Glob Health       Date:  2017-06       Impact factor: 4.413

5.  The association of a reduced susceptibility to moxifloxacin in causative Clostridium (Clostridioides) difficile strain with the clinical outcome of patients.

Authors:  Marcela Krutova; Vaclav Capek; Elka Nycova; Sabina Vojackova; Magda Balejova; Lenka Geigerova; Renata Tejkalova; Lenka Havlinova; Iva Vagnerova; Pavel Cermak; Lenka Ryskova; Petr Jezek; Dana Zamazalova; Denisa Vesela; Alice Kucharova; Dana Nemcova; Martina Curdova; Otakar Nyc; Pavel Drevinek
Journal:  Antimicrob Resist Infect Control       Date:  2020-06-30       Impact factor: 4.887

6.  Process and outcome indicators for infection control and prevention in European acute care hospitals in 2011 to 2012 - Results of the PROHIBIT study.

Authors:  Sonja Hansen; Frank Schwab; Walter Zingg; Petra Gastmeier
Journal:  Euro Surveill       Date:  2018-05

7.  Prevalence and Strain Characterization of Clostridioides (Clostridium) difficile in Representative Regions of Germany, Ghana, Tanzania and Indonesia - A Comparative Multi-Center Cross-Sectional Study.

Authors:  Mwanaisha Seugendo; Iryna Janssen; Vanessa Lang; Irene Hasibuan; Wolfgang Bohne; Paul Cooper; Rolf Daniel; Katrin Gunka; R L Kusumawati; Stephen E Mshana; Lutz von Müller; Benard Okamo; Jan R Ortlepp; Jörg Overmann; Thomas Riedel; Maja Rupnik; Ortrud Zimmermann; Uwe Groß
Journal:  Front Microbiol       Date:  2018-08-07       Impact factor: 5.640

8.  Epidemiology of Clostridioides difficile infections, France, 2010 to 2017.

Authors:  Mélanie Colomb-Cotinat; Laetitia Assouvie; Julien Durand; Côme Daniau; Lucie Leon; Sylvie Maugat; Sophan Soing-Altrach; Cécile Gateau; Jeanne Couturier; Isabelle Arnaud; Pascal Astagneau; Anne Berger-Carbonne; Frédéric Barbut
Journal:  Euro Surveill       Date:  2019-08

9.  Incidence and Outbreak of Healthcare-Onset Healthcare-Associated Clostridioides difficile Infections Among Intensive Care Patients in a Large Teaching Hospital in China.

Authors:  Chunhui Li; Yuan Li; Yang Huai; Sidi Liu; Xiujuan Meng; Juping Duan; John D Klena; Jeanette J Rainey; Anhua Wu; Carol Y Rao
Journal:  Front Microbiol       Date:  2018-03-27       Impact factor: 5.640

10.  Global burden of Clostridium difficile infections: a systematic review and meta-analysis.

Authors:  Evelyn Balsells; Ting Shi; Callum Leese; Iona Lyell; John Burrows; Camilla Wiuff; Harry Campbell; Moe H Kyaw; Harish Nair
Journal:  J Glob Health       Date:  2019-06       Impact factor: 4.413

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.